Astellas/Medivation seek FDA nod to expand Xtandi mCRPC use
This article was originally published in Scrip
Executive Summary
Astellas Pharma and Medivation are seeking to expand the US labeling for Xtandi enzalutamide), an androgen receptor inhibitor, as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy.